186 related articles for article (PubMed ID: 1844697)
1. Bioequivalence and intrasubject variability.
Liu JP
J Biopharm Stat; 1991; 1(2):205-19. PubMed ID: 1844697
[TBL] [Abstract][Full Text] [Related]
2. Assessment of bioequivalence using a multiplicative model.
Chow SC; Peace KE; Shao J
J Biopharm Stat; 1991; 1(2):193-203. PubMed ID: 1844696
[TBL] [Abstract][Full Text] [Related]
3. On assessment of bioequivalence under a higher-order crossover design.
Chow SC; Liu JP
J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
[TBL] [Abstract][Full Text] [Related]
4. A three-step procedure for assessing bioequivalence in the general mixed model framework.
Vuorinen J; Turunen J
Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
[TBL] [Abstract][Full Text] [Related]
5. A new approach for outliers in a bioavailability/bioequivalence study.
Liao JJ
J Biopharm Stat; 2007; 17(3):393-405. PubMed ID: 17479389
[TBL] [Abstract][Full Text] [Related]
6. An area correction method to reduce intrasubject variability in bioequivalence studies.
Abdallah HY
J Pharm Pharm Sci; 1998; 1(2):60-5. PubMed ID: 10945919
[TBL] [Abstract][Full Text] [Related]
7. Assessment of selection bias in estimates of relative bioavailability and intrasubject variability from bioequivalence evaluations.
Wang Y
J Biopharm Stat; 2000 Aug; 10(3):407-24. PubMed ID: 10959920
[TBL] [Abstract][Full Text] [Related]
8. Average bioequivalence for two-sequence two-period crossover design with incomplete data.
Lee JY; Kim BC; Park SG
J Biopharm Stat; 2005; 15(5):857-67. PubMed ID: 16078389
[TBL] [Abstract][Full Text] [Related]
9. A two one-sided tests procedure for assessment of individual bioequivalence.
Liu J; Chow SC
J Biopharm Stat; 1997 Mar; 7(1):49-61. PubMed ID: 9056588
[TBL] [Abstract][Full Text] [Related]
10. Types of bioequivalence and related statistical considerations.
Hauck WW; Anderson S
Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
[TBL] [Abstract][Full Text] [Related]
11. Robust and bootstrap testing procedures for bioequivalence.
Shen CF; Iglewicz B
J Biopharm Stat; 1994 Mar; 4(1):65-90. PubMed ID: 8019585
[TBL] [Abstract][Full Text] [Related]
12. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
Esinhart JD; Chinchilli VM
J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
[TBL] [Abstract][Full Text] [Related]
13. Optimal sampling times in bioequivalence tests.
Kong FH; Gonin R
J Biopharm Stat; 2000 Feb; 10(1):31-44. PubMed ID: 10709799
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
[TBL] [Abstract][Full Text] [Related]
15. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
16. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
Rasmussen HE; Ma R; Wang JJ
Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
[TBL] [Abstract][Full Text] [Related]
17. Optimization of testing times and critical values in sequential equivalence testing.
Müller HH; Schäfer H
Stat Med; 1999 Jul; 18(14):1769-88; discussion 1789. PubMed ID: 10407247
[TBL] [Abstract][Full Text] [Related]
18. The analysis of bioequivalence with respect to TMAX under a 2 x 2 crossover design.
Have TR; Ten Chinchilli VM
J Biopharm Stat; 1995 Jul; 5(2):185-99. PubMed ID: 7581427
[TBL] [Abstract][Full Text] [Related]
19. Sequential designs for equivalence studies.
Whitehead J
Stat Med; 1996 Dec; 15(24):2703-15. PubMed ID: 8981681
[TBL] [Abstract][Full Text] [Related]
20. Statistical aspects of comparative bioavailability trials.
Westlake WJ
Biometrics; 1979 Mar; 35(1):273-80. PubMed ID: 583027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
